Impact of Simultaneous Itch Relief and Substantial Skin Clearance With Lebrikizumab in Patients With Atopic Dermatitis: Post-hoc Analysis From ADvocate1/2
Main Article Content
Keywords
atopic dermatitis, lebrikizumab, health-related quality of life, itch relief, patient-reported outcomes, Sleep loss
References
2. Okragly AJ, et al. Dermatol Ther. 2023;13:1535-1547.
3. EBGLYSS (lebrikizumab-lbkz), injection, for subcutaneous use. Prescribing information. Eli Lilly and Company. 2025.
4. Silverberg JI, et al. N Engl J Med. 2023;388:1080-91.
5. Thaçi D, et al. Lebrikizumab provides skin clearance and itch relief at week 16 and week 52: pooled results from 2 phase 3 studies ADvocate1 and ADvocate2. Presented at EADV Congress 2025.
6. Silverberg JI, et al. J Dermatolog Treat. 2024;35:2428729.
7. Silverberg JI, et al. Dermatol Ther. 2025;15:2255-2273.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.